ImmunoPrecise Antibodies Announces Restructuring of Management Team ImmunoPrecise Antibodies (IPA) (NASDAQ: IPA), an AI-driven biotherapeutics discovery and technology company, is excited to share several important leadership changes. Kamil Isaev has…
Healx Doses First Patient in Phase 2 Trial of HLX-1502 for Neurofibromatosis Type 1 Healx, a clinical-stage biotech company utilizing AI to advance treatments for rare diseases, has announced that…
PepGen Announces Positive Results from FREEDOM-DM1 Trial in DM1 Patients PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide therapies, recently announced promising early results from…
FDA Accepts Bristol Myers Squibb’s Application for Opdivo® + Yervoy® in MSI-High or MMR-Deficient Cancer Bristol Myers Squibb (NYSE: BMY) recently announced that the U.S. Food and Drug Administration (FDA)…
Almirall 2024 Results: Surpasses Guidance, Poised for Sustained Growth Almirall, S.A., a global biopharmaceutical company based in Barcelona, has reported strong financial results for the full year of 2024. The…
Triastek’s D23 (Budesonide Ileum-Targeted Tablet) Shows Positive Clinical Results Triastek has announced that its 3D-printed drug, D23 (Budesonide Ileum-Targeted Tablet), has achieved positive results in a recent clinical trial aimed…
Sensorion Receives Positive Recommendation for Audiogene Trial of SENS-501 Sensorion, a clinical-stage biotechnology company focused on developing novel therapies to treat and prevent hearing loss, has announced a positive recommendation…
Allurion Closes Offering and Private Placement to Advance GLP-1 Pipeline Allurion Technologies, Inc. (NYSE: ALUR), a company focused on ending obesity, announced the successful closing of its previously announced registered…
OS Therapies Granted Patent for OST-HER2 Commercial Manufacturing OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company focused on immunotherapies and targeted drug conjugates for cancer treatment, announced today that…
Stablepharma Secures €2.5M EIC Grant, Among Top 71 EU Innovators UK biotech Stablepharma Ltd has secured a €2.5M grant from the European Innovation Council (EIC) Accelerator Programme. The funding acknowledges…
Stablepharma Secures €2.5M EIC Grant, Named Top EU Innovator UK-based biotechnology firm Stablepharma Ltd has been awarded €2.5 million through the prestigious European Innovation Council (EIC) Accelerator program. The grant…
Arcus Biosciences Retains Casdatifan Rights and Announces $150M Stock Offering Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage global biopharmaceutical company specializing in cancer treatments, announced today that Gilead’s exclusive option rights…